India's Max Healthcare gains as brokerage starts with 'buy'
Hospital operator Max Healthcare MAXE.NS climbs 1.6% to 1,171.1 rupees
Nuvama initiates coverage with "buy" rating, PT of 1,430 rupees - implying 24% upside to last close
Says MAXE is set for strong volume-led growth as capacity doubles by FY29; expects revenue CAGR of 20% over FY25-28
Adds, co likely to retain leadership in North India, backed by tech-driven clinical solutions, lower attrition, strong balance sheet and healthy cash flow
MAXE is rated "buy" on avg by 20 analysts, same as rival Apollo Hospitals APLH.NS by 26 analysts - data compiled by LSEG
Median PT on MAXE 1,310 rupees, APLH at 8,788 rupees
YTD, MAXE up nearly 4% vs about 8% rise in APLH
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
SanDisk Surges 8% as Earnings Countdown Begins - Here's What Every Investor Needs to Know

Azure Growth 40%, AI Revenue 37 Billion: Why Did Microsoft Shares Fall Instead of Rise?

Nvidia Stock Prediction: Can NVDA Hit $1,000 by 2030?

Robinhood Slumps 8% After Earnings. Revenue and Profit Both Miss, Market Fears Coinbase May Follow Suit.

GOOGL Vs. MSFT: 2 Monster Stocks to Hold for the Next 5 Years

Tradingkey







